Abbott India LtdNSE: ABBOTINDIA
Open the Abbott India Ltd page
Follow Abbott India LtdFree account. Get a note when Abbott India Ltd files.
Q1 FY27 results analysis · August 12, 2026

Abbott India Ltd (ABBOTINDIA) Q1 FY27 Results Analysis: PAT Jumps 17%, Revenue Lags Industry

+17.1%PAT year on year, Rs. 428.52 Cr
Cofacto ResearchPublished August 12, 20262 min readNeutral read
Quick summary

Abbott India Ltd's Q1 FY27 numbers came in mixed, with revenue of Rs. 1,813.68 Cr (+4.33% YoY) and PAT growth of +17.13% YoY. Here's a quick read of what worked, what to watch, and what management said.

Quick Details
Results dateAugust 12, 2026
QuarterQ1 FY 2026-2027
Revenue (Q1)Rs. 1,813.68 Cr (+4.33% YoY)
PAT (Q1)Rs. 428.52 Cr (+17.13% YoY)
EBITDA margin32.96% (+314 bps YoY)
EPS (Q1)Rs. 201.66 (+17.13% YoY)
Market capRs. 59,821.41 Cr
CMPRs. 28,140.00

Quarter Snapshot

Revenue growth decelerated to 4.33% YoY, lagging industry growth, but PAT grew 17% due to operating leverage and cost controls. EBITDA margin expanded 314bps YoY, partly from a temporary inventory-FX benefit expected to reverse. Weak top-line performance relative to peers is a concern.

Key Investment Insights

Key Positives

  • Revenue grew 4.33% YoY to Rs.1,813.68 Cr.
  • PAT grew 17.13% YoY to Rs.428.52 Cr.
  • EBITDA margin expanded 314 bps YoY to 32.96%.
  • Employee cost growth slowed to 4.30% YoY from 13.8% in FY26.
  • Inventory build reduced to Rs.31.10 Cr from Rs.72.85 Cr YoY.

Risk Factors

  • Revenue growth decelerated to 4.33% YoY, below FY26's 8.1% and below IPM estimate of ~11.3%, indicating possible market share loss.
  • EBITDA margin expansion of 314 bps was partly driven by temporary inventory-FX benefit; purchases ratio expected to revert to 48-50% as old stock is replaced.

Ask about this

Ask Cofacto a question about this result. Answers cite filings and company data.

Companies on this page

Related

Share on X · LinkedIn · WhatsApp

Disclaimer: This results analysis is published for educational and informational purposes only. It is not investment advice, not a recommendation to buy, sell or hold any security.